Effective inhibition of these alternative immune checkpoints may prove a promising therapeutic strategy, especially in PD-L1 negative NSCLC, which has been shown to express these alternative molecules widely or in association with primary resistance to PD-1/PD-L1 blockade [14]. Here, CD274 is linked to non-small cell lung carcinoma.